Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma

Table 1 Baseline characteristics for patients, n (%)

Variables	Patients (n = 40)
Sex
Male	34 (85)
Female	6 (15)
Age, yr	55 ± 9
HBsAg
Positive	30 (75)
Negative	10 (25)
Alb (g/L)	38.7 ± 4.7
AFP (ng/mL)
< 400	26 (65)
≥ 400	14 (35)
Child-Pugh class
A	34 (85)
B	6 (15)
Tumor-number
Solitary	18 (45)
Multiple	22 (55)
Max-diameter (cm)	5.4 ± 3.3
Extrahepatic metastasis	14 (35)
PVTT
Left	6 (15)
Right	23 (57.5)
None	11 (27.5)
Tumor distribution
Uni-lobar	35 (87.5)
Bi-lobar	5 (12.5)

HBsAg: Hepatitis B surface antigen; ALB: Albumin; AFP: Alpha fetoprotein; PVTT: Portal vein tumor thrombus.

Table 2 Tumor best response, n (%)

Response	Patients (n = 40)
CR	5 (12.5)
PR	13 (32.5)
SD	18 (45)
PD	4 (10)
ORR	18 (45)
DCR	36 (90)

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.

Table 3 common treatment-related adverse events, n (%)

Adverse events	Grade 1/2	Grade 3/4	Any grade
Fatigue	13 (32.5)	0	13 (32.5)
Anorexia	5 (12.5)	0	5 (12.5)
Leukocytopenia	15 (37.5)	0	15 (37.5)
Increased alanine aminotransferase	27 (67.5)	1 (2.5)	28 (70)
Increased aspartate aminotransferase	24 (60)	1 (2.5)	25 (62.5)
Thrombocytopenia	9 (22.5)	1 (2.5)	10 (25)
Hypertension	12 (30)	0	12 (30)
Hand-foot skin reaction	13 (32.5)	2 (5)	15 (37.5)
Diarrhea	3 (7.5)	0	3 (7.5)
Hypothyroidism	5 (12.5)	0	5 (12.5)
Hyperthyroidism	1 (2.5)	0	1 (2.5)
Emaciation	6 (15)	0	6 (15)
Fever	10 (12.5)	0	10 (12.5)
Pain	19 (47.5)	0	19 (47.5)
Proteinuria	3 (7.5)	1 (2.5)	4 (10)
Elevated bilirubin	5 (12.5)	0	5 (12.5)
Autoimmune hemolytic anemia	0	1 (2.5)	1 (2.5)